The ASCO Daily News spoke recently with Edward S. Kim, MD, of the Carolinas Healthcare System Levine Cancer Institute, about key data presented during the 2018 ASCO Annual Meeting regarding drug activity across tumor types.
The explosion of precision medicine and genomics research over the last decade or more has revolutionized the field of oncology. Two Education Sessions will offer updates on genomics research along with practical advice about how to incorporate precision medicine techniques into practice.
Dr. Eric Kmiec summarizes advances in real-time gene editing and cancer immunotherapy. Such advances, including CTLA-4 and PD-1 blockade, as well as CRISPR/Cas9 and CAR-based manipulations, are being explored in multiple ongoing clinical trials worldwide.
Authors discuss the most up-to-date research on using chemotherapy treatments for good-risk germ cell tumors, focusing on the use of post-chemotherapy retroperitoneal lymph node dissection and the need for continued, longer-term studies.
SIOPEN results presented at the 2011 ASCO Plenary Session changed the standard of care for high-risk neuroblastoma in Europe but not in North America. Standard of care in North America now is tandem autologous stem cell transplants.
CALGB/SWOG 80405 as well as a large population-based study report on clinical outcomes in patients with advanced colorectal cancers based on the location of the primary tumor. Do left-sided tumors fare better than right-sided tumors and what are the implications for clinical practice?
Dr. William G. Kaelin is honored with the 2016 Science of Oncology Award and Lecture for providing new insights into the biochemical functions of tumor suppressor proteins and their role in cancer development.
The EGFR signaling pathway is one of the most important for regulation of growth, proliferation, and differentiation in mammalian cells. Overexpression of EGFR and its ligands has been demonstrated in many types of tumors such as lung and breast cancers, CRCs, HNSCC, and glioblastoma.
The B-cell receptor pathway has recently become a target for treatment of many incurable B-cell malignancies, including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic leukemia, and chronic lymphocytic leukemia.
The discovery of postnatal activation of the fundamental developmental Hedgehog (Hh) signaling pathway has opened a new field for pharmaceutical intervention and modulation. Several Hh pathway antagonists have been evaluated in phase I and II trials, and at least two have been approved for use.
Data presented at a clinical science symposium stated that nivolumab may be a promising treatment for patients with advanced hepatocellular carcinoma, while patients with tumors having genetic defects in mismatch repair respond significantly better to therapy with the PD-1 inhibitor pembrolizumab.
Continuing bevacizumab beyond progression confers no apparent clinical benefit in recurrent glioblastoma patients compared with cessation of the drug, according to results of the second part of a randomized trial. Neither progress-free survival nor OS was any different with continuing bevacizumab.